JAHA:老年人血管危险因素和APOE基因型与血管周间隙的关系

2020-08-05 MedSci原创 MedSci原创

这项研究提供了有限的证据支持老年人磁共振成像上PVS与传统血管危险因素之间存在相关性。直立性低血压与APOEε4携带者脑叶PVS的关联表明,脑叶PVS可能是淀粉样蛋白相关小血管疾病的标志。

有证据表明,扩大的血管周间隙(PVS)可能是脑小血管疾病的标志。近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员旨在调查老年人血管危险因素是否与PVS相关。

这项基于人群的研究纳入了530名参与者(≥60岁),他们没有痴呆症和功能依赖,这些参与者来自瑞典衰老和护理的国家研究(2001-2003年)。研究人员通过访谈、临床检查、实验室检查和患者登记收集了参与者有关人口统计学、血管危险因素和健康状况的数据。研究人员采用半定量视觉评定量表视觉评估磁共振图像上大脑PVS和白质高强度,并使用一般线性回归模型分析数据。

在控制了人口统计学和心血管疾病之后,极高的血压(≥160/100 mmHg)与总体PVS评分显著相关(β系数为1.30;95%CI为0.06-2.53),体位性低血压与基底神经节PVS评分相关(β系数为0.37;0.03–0.70),但是当调整白质超高负荷时,相关性变得不显著。体位性低血压与APOEε4等位基因携带者的总体和脑叶PVS评分显著相关,而与非携带者无关。总体或区域性PVS评分与其他传统的血管危险因素(例如吸烟、糖尿病、缺乏运动以及超重或肥胖)没有显著相关性。

由此可见,这项研究提供了有限的证据支持老年人磁共振成像上PVS与传统血管危险因素之间存在相关性。直立性低血压与APOEε4携带者脑叶PVS的关联表明,脑叶PVS可能是淀粉样蛋白相关小血管疾病的标志。

原始出处:

Anna Laveskog.et al.Associations of Vascular Risk Factors and APOE Genotype With Perivascular Spaces Among Community‐Dwelling Older Adults.J AM HEART ASSOC.2020.https://www.ahajournals.org/doi/full/10.1161/JAHA.119.015229

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1890874, encodeId=471718908e4ed, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jun 17 23:06:51 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785943, encodeId=a0df1e85943d6, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Aug 05 15:06:51 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948950, encodeId=058c194895091, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 27 23:06:51 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268304, encodeId=2b151268304e6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506188, encodeId=c8851506188a2, content=<a href='/topic/show?id=920726e153' target=_blank style='color:#2F92EE;'>#APOE基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2671, encryptionId=920726e153, topicName=APOE基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e369715389, createdName=yytms, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590608, encodeId=978c159060869, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1890874, encodeId=471718908e4ed, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jun 17 23:06:51 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785943, encodeId=a0df1e85943d6, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Aug 05 15:06:51 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948950, encodeId=058c194895091, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 27 23:06:51 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268304, encodeId=2b151268304e6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506188, encodeId=c8851506188a2, content=<a href='/topic/show?id=920726e153' target=_blank style='color:#2F92EE;'>#APOE基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2671, encryptionId=920726e153, topicName=APOE基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e369715389, createdName=yytms, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590608, encodeId=978c159060869, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1890874, encodeId=471718908e4ed, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jun 17 23:06:51 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785943, encodeId=a0df1e85943d6, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Aug 05 15:06:51 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948950, encodeId=058c194895091, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 27 23:06:51 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268304, encodeId=2b151268304e6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506188, encodeId=c8851506188a2, content=<a href='/topic/show?id=920726e153' target=_blank style='color:#2F92EE;'>#APOE基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2671, encryptionId=920726e153, topicName=APOE基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e369715389, createdName=yytms, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590608, encodeId=978c159060869, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1890874, encodeId=471718908e4ed, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jun 17 23:06:51 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785943, encodeId=a0df1e85943d6, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Aug 05 15:06:51 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948950, encodeId=058c194895091, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 27 23:06:51 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268304, encodeId=2b151268304e6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506188, encodeId=c8851506188a2, content=<a href='/topic/show?id=920726e153' target=_blank style='color:#2F92EE;'>#APOE基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2671, encryptionId=920726e153, topicName=APOE基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e369715389, createdName=yytms, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590608, encodeId=978c159060869, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
    2020-08-07 zhaohui6731
  5. [GetPortalCommentsPageByObjectIdResponse(id=1890874, encodeId=471718908e4ed, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jun 17 23:06:51 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785943, encodeId=a0df1e85943d6, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Aug 05 15:06:51 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948950, encodeId=058c194895091, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 27 23:06:51 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268304, encodeId=2b151268304e6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506188, encodeId=c8851506188a2, content=<a href='/topic/show?id=920726e153' target=_blank style='color:#2F92EE;'>#APOE基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2671, encryptionId=920726e153, topicName=APOE基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e369715389, createdName=yytms, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590608, encodeId=978c159060869, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
    2020-08-07 yytms
  6. [GetPortalCommentsPageByObjectIdResponse(id=1890874, encodeId=471718908e4ed, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Thu Jun 17 23:06:51 CST 2021, time=2021-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785943, encodeId=a0df1e85943d6, content=<a href='/topic/show?id=ba23e193b2' target=_blank style='color:#2F92EE;'>#E基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7193, encryptionId=ba23e193b2, topicName=E基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Aug 05 15:06:51 CST 2020, time=2020-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948950, encodeId=058c194895091, content=<a href='/topic/show?id=1e4789584b0' target=_blank style='color:#2F92EE;'>#血管危险因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89584, encryptionId=1e4789584b0, topicName=血管危险因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Thu May 27 23:06:51 CST 2021, time=2021-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268304, encodeId=2b151268304e6, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506188, encodeId=c8851506188a2, content=<a href='/topic/show?id=920726e153' target=_blank style='color:#2F92EE;'>#APOE基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2671, encryptionId=920726e153, topicName=APOE基因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e369715389, createdName=yytms, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1590608, encodeId=978c159060869, content=<a href='/topic/show?id=c80a2666f2' target=_blank style='color:#2F92EE;'>#APOE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2666, encryptionId=c80a2666f2, topicName=APOE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ff9817837767, createdName=xiongke016, createdTime=Fri Aug 07 05:06:51 CST 2020, time=2020-08-07, status=1, ipAttribution=)]
    2020-08-07 xiongke016

相关资讯

SCI REP:中国卒中亚型和血管危险因素的变化趋势!

总之,卒中亚型的比例发生了显著变化。需要加强降压治疗来控制ICH、SAH和SVD缺血性卒中的发生率。提高IS的病因学检测及降脂治疗是有效的,心源性栓塞的检测也进一步加强。

Neurology:脑出血人口学特征、部位、血管危险因素存在性别差异

背景:脑出血相关的性别差异的信息较少。这是一项前瞻性观察研究来描述原发性脑出血人口统计学,血管危险因素及卒中护理和预后的性别差异。方法:BasicMar登记入住公立医院的卒中患者的记录,共覆盖人口330000。从2005到2015年,共有515例急性原发性脑出血患者。获得3个月预后记录。结果:发生脑出血男性高于女性(52.4% vs 47.6%);发生脑出血的女性年龄高于男性,女性以前功能状态更差

卒中血管危险因素影响静脉注射组织型纤溶酶原激活剂的结局

静脉注射(IV)组织型纤溶酶原激活剂(tPA)是唯一批准用于急性缺血性脑卒中非侵入性治疗方案。但tPA治疗后,卒中不同亚型依据血管危险因素的结局仍有待阐明。近日,发表在PLOS one上的一项研究探索了不同急性缺血性脑卒中亚型IV tPA治疗后结局与不同危险因素的关系。基于国家健康研究院的卒中测量(NIHSS)评分、90天改进的Rankin评分(mRS)和卒中亚型,研究收集和分析了人口基线资料和血

Stroke:卒中复发及卒中后痴呆与卒中前血管危险因素相关

背景:改善脑卒中后短期生存有必要量化长期后遗症(即复发性中风和痴呆)的风险及危险因素。这种风险可能会受卒中前心血管疾病的危险因素的影响。在鹿特丹以人口为基础的研究中,研究者确定复发性卒中和痴呆长期风险,并探讨了卒中前心血管危险因素影响复发性卒中和卒中后痴呆症的比例。(即人群归因危险度)。方法:研究者随访了1237例首发的脑卒中患者和,按照年龄,性别,检查周期及卒中日期(指数日期)相匹配的4928无